Nuotio-Antar AM, Hachey DL, Hasty AH. Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice. Am J Physiol Endocrinol Metab 293: E1517-E1528, 2007. First published September 18, 2007; doi:10.1152/ajpendo.00522.2007.-Glucocorticoids, which are well established to regulate body fat mass distribution, adipocyte lipolysis, hepatic gluconeogenesis, and hepatocyte VLDL secretion, are speculated to play a role in the pathology of metabolic syndrome. Recent focus has been on the activity of 11␤-hydroxysteroid dehydrogenase type 1 (11␤-HSD1), which is capable of regenerating, and thus amplifying, glucocorticoids in key metabolic tissues such as liver and adipose tissue. To determine the effects of global 11␤-HSD1 inhibition on metabolic syndrome risk factors, we subcutaneously injected "Western"-type diet-fed hyperlipidemic mice displaying moderate or severe obesity [LDL receptor (LDLR)-deficient (LDLR Ϫ/Ϫ ) mice and mice derived from heterozygous agouti (A y /a) and homozygous LDLR Ϫ/Ϫ breeding pairs (A y /a;LDLR Ϫ/Ϫ mice)] with the nonselective 11␤-HSD inhibitor carbenoxolone for 4 wk. Body composition throughout the study, end-point fasting plasma, and extent of hepatic steatosis and atherosclerosis were assessed. This route of treatment led to detection of high levels of carbenoxolone in liver and fat and resulted in decreased weight gain due to reduced body fat mass in both mouse models. However, only A y /a;LDLR Ϫ/Ϫ mice showed an effect of 11␤-HSD1 inhibition on fasting insulin and plasma lipids, coincident with a reduction in VLDL due to mildly increased VLDL clearance and dramatically decreased hepatic triglyceride production. A y /a;LDLR Ϫ/Ϫ mice also showed a greater effect of the drug on reducing atherosclerotic lesion formation. These findings indicate that subcutaneous injection of an 11␤-HSD1 inhibitor allows for the targeting of the enzyme in not only liver, but also adipose tissue, and attenuates many metabolic syndrome risk factors, with more pronounced effects in cases of severe obesity and hyperlipidemia.
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11␤-hydroxysteroid dehydrogenase type 1; obesity; agouti; low-density lipoprotein receptor THE OBESITY EPIDEMIC is a world-wide health problem (5) . Of major concern to health care professionals is the accompanying rise in other metabolic syndrome risk factors associated with severe obesity: dyslipidemia, hypertension, and impaired glucose homeostasis, which further predispose patients to cardiovascular disease and diabetes (6) . Cushing's syndrome, characterized by excess circulating endogenously or exogenously derived glucocorticoids, results in metabolic syndrome symptoms, such as central obesity, increased plasma triglycerides (TGs), hypertension, and elevated fasting glucose (38, 55) . Glucocorticoids impact body fat distribution and stimulate adipocyte differentiation and lipolysis (19, 21, 48) . In hepatocytes, glucocorticoids modulate gluconeogenic and lipogenic processes (14, 53) . Because obesity is not frequently associated with excess circulating glucocorticoids, there is speculation that enhanced actions of glucocorticoids in key metabolic tissues, such as adipose tissue and liver, may play a causative role in the altered physiology observed in patients with metabolic syndrome (43) .
11␤-Hydroxysteroid dehydrogenase (11␤-HSD) type 1 (11␤-HSD1) is a bidirectional NADP ϩ /NADPH-dependent dehydrogenase/reductase that is highly expressed in key metabolic tissues such as liver and adipose tissue, where it acts primarily to regenerate glucocorticoids from inactive, 11-keto metabolites (33) . A second isoform, 11␤-HSD2, the product of a different gene, acts solely to metabolize glucocorticoids and is highly expressed in tissues such as kidney, where it confers protection against excess binding of glucocorticoids to the mineralocorticoid receptor (32, 49) . Thus, 11␤-HSD1 is the only enzyme capable of regenerating corticosterone from 11-dehydrocorticosterone (11-DHC) in rodents or cortisol from cortisone in humans. As these 11-keto metabolites circulate at high concentrations (24, 57) , 11␤-HSD1 activity may serve to potentiate local concentrations of active glucocorticoids in a tissue-specific manner, preventing the need for the body to produce excess circulating receptor-competent glucocorticoid isoforms, which may have deleterious effects in other tissues.
Dysregulated 11␤-HSD1 activity can profoundly affect metabolic phenotype in mice. Adipose tissue-specific 11␤-HSD1 overexpression results in hypertension, increased serum free fatty acid (FFA) and TG levels, insulin resistance, central obesity, and hypertension (30, 31) . Liver-specific 11␤-HSD1 amplification results in hypertension, a proatherogenic lipoprotein profile, and non-obesity-associated hyperinsulinemia (42) . Conversely, global 11␤-HSD1 deficiency in mice fed a highfat diet is associated with decreased weight gain and improved serum HDL lipoprotein profiles, despite increased adrenocortex-derived circulating glucocorticoids (24, 34, 35) . Therefore, it appears that 11␤-HSD1 activity may potentially impact more than one risk factor for metabolic syndrome. Inasmuch as 11␤-HSD1 expression has been reported to be increased in the adipose tissue of obese patients (10, 22, 46) , this enzyme may prove to be a promising drug target for patients with the metabolic syndrome.
No study has assessed metabolic outcomes of 11␤-HSD1 inhibition in the context of combined obesity, atherogenesis, and hyperlipidemia, nor have the effects of 11␤-HSD1 inhibition on lipoprotein metabolism in such a context been characterized, which would be key to determining effects of such drugs on dyslipidemia in patients with metabolic syndrome. In this study, we administered subcutaneous injections of the nonselective 11␤-HSD inhibitor carbenoxolone (CBX) to hyperlipidemic, Western-type diet (WD)-fed moderately obese LDL receptor (LDLR)-deficient (LDLR Ϫ/Ϫ ) and severely obese mice derived from heterozygous agouti (A y /a) and homozygous LDLR Ϫ/Ϫ breeding pairs (A y /a; LDLR Ϫ/Ϫ mice) (11, 12) and examined outcomes on various metabolic syndrome risk factors. We found that systemic inhibition of 11␤-HSD1 led to dramatic improvements in body composition, basal metabolic rate, insulin resistance, lipoprotein metabolism, hepatic steatosis, and atherosclerosis in the more severely obese and insulin-resistant mice, suggesting that targeting this enzyme may become a key therapy for patients with multiple metabolic syndrome risk factors. being maintained on WD. Mice were weighed and total fat and lean mass were assessed weekly using an NMR analyzer (Minispec, Bruker Optics) during the 4 wk of treatment. Unless otherwise noted, at the end of the study, all mice were fasted for 5 h and injected 1 h before they were killed, anesthetized, bled by puncture of the retroorbital venous plexus, euthanized with isoflurane inhalation followed by cervical dislocation, perfused with PBS, and dissected for further tissue analyses. Plasma was separated from whole blood by centrifugation at 4°C.
MATERIALS AND METHODS

Mice
11␤-HSD1 enzyme assays. 11␤-HSD1 activity was analyzed as previously described (39) using 5 g of liver and 50 g of gonadal fat pad protein from tissue homogenates and a total concentration of 20 M cortisone substrate and 1.2 mM NADPH co-substrate per assay after determination of optimal protein concentrations of liver and adipose tissue homogenates.
Ultraperformance liquid chromatography-tandem mass spectrometry analysis of tissues. Sample preparation and liquid chromatography (LC)-tandem mass spectrometry (MS-MS) analysis were performed according to the method of Ronquist-Nii and Edlund (50) with modifications (see supplemental information online at the American Journal of Physiology-Endocrinology and Metabolism website).
Systolic blood pressure measurement. Systolic blood pressure was measured in conscious, resting mice by tail cuff plethysmography as previously described (59) . During the last week of treatment, vehicle and 50 mg ⅐ kg Ϫ1 ⅐ day Ϫ1 CBX were administered to male and female A y /a;LDLR Ϫ/Ϫ and LDLR Ϫ/Ϫ mice, the animals were trained for 3 consecutive days, and baseline systolic blood pressure was measured and averaged over the 2 succeeding days.
Food intake. For studies measuring food intake, mice were separated by genotype and housed in initially weight-matched groups of two or three mice per cage. Weighing error due to food spillage was minimized by using large, intact food pellets throughout the study and by including in the food weight assessments Ͼ0.1-g remnants of food pellets found in cage bedding. Food intake efficiency over the 4-wk treatment period was calculated using the following equation: efficiency ϭ (total change in body weight/cumulative food intake) ϫ 100.
Indirect calorimetry. At the end of the 1st wk of treatment, singly housed, weight-matched female A y /a;LDLR Ϫ/Ϫ mice were placed in metabolic cages for 24 h of acclimation followed by 24 h of measurement. Whole body O 2 consumption (V O2), CO2 production (V CO2), and activity were measured continuously for 1 min at 15-min intervals using an indirect calorimetry system (Oxymax Deluxe, Columbus Instruments) with an airflow rate of 0.6 l/min. Oxymax software used the following equations to calculate respiratory exchange ratio (RER) and energy expenditure (heat): RER ϭ V CO2/V O2 and heat ϭ (3.815 ϩ 1.232 ϫ RER) ϫ V O2 (40) . Heat was then normalized to lean body mass. Basal metabolic rate for each mouse was calculated by averaging heat from three 45-min intervals of least energy expenditure during the light cycle.
Plasma analyses. Plasma TG, total cholesterol (TC), and FFA were measured using TG and cholesterol reagents (Raichem) and the NEFA C kit (Wako), respectively. Blood glucose was measured using a Lifescan One Touch basic glucometer kit (Johnson & Johnson). Insulin and leptin were determined using modified insulin doubleantibody RIA kits (Linco Research). Lipoprotein fractionation was achieved by fast protein LC using aliquots of pooled plasma samples from each group of mice. Plasma samples from mice used for VLDL turnover and hepatic TG production experiments were omitted from end-point plasma lipid analysis.
VLDL turnover. Plasma from fasted age-matched, WD-fed, overnight-fasted A y /a;LDLR Ϫ/Ϫ mice was pooled, and VLDL (density Ͻ1.019 g/l) was isolated by density gradient ultracentrifugation in a centrifuge (Optima TLX, Beckman Coulter). IODO-GEN precoated reaction tubes (Pierce Biotechnology) were used to incorporate 125 I Hepatic TG production. Blood was collected from overnight-fasted male and female mice for baseline TG analysis. Mice were injected with tyloxapol (Sigma-Aldrich; 500 mg/kg body wt) to inhibit TG clearance. Mice were bled 1 and 2 h after injection, and plasma was analyzed for TG content. Hepatic TG production rate was linear over the time course and was calculated as the slope of the plasma TG vs. time curve from baseline to 2 h.
Aortic root lesion area quantification. Sections (10 m) of aortic root from frozen, OCT-embedded hearts were cut according to the method of Paigen et al. (41) . Cryosections were stained with oil red O (Sigma-Aldrich) for detection of neutral lipids and counterstained with Mayer's hematoxylin. A Q-Imaging Micropublisher camera attached to an Olympus light microscope and Histometrix 6 software (Kinetic Imaging) were used to capture images and quantify aortic root lesion areas.
Liver neutral lipid staining. Cryosections (10 m) from livers of representative female mice from each treatment group were cut, mounted, and stained, and images were captured as described previously for aortic root lesions.
Liver lipid quantification. Liver lipids were extracted and quantified using a gas chromatography-flame ionization detector system as described previously (52) .
Gene expression quantification. Total RNA was extracted from livers, and gene expression was quantified using an ABI Prism 7700 sequence detection system (Applied Biosystems) and validated Assays-on-Demand primers with 6-carboxyfluorescein dye-MGB-labeled TaqMan probes as previously described (39). 
RESULTS
Measurement of CBX and its effects in liver and adipose tissue.
To study effects of 11␤-HSD1 inhibition in a mouse model of hyperlipidemia and obesity, we chose to use hyperlipidemic hyperphagic A y /a;LDLR Ϫ/Ϫ mice, which are a mouse model of maturity-onset obesity when fed a chow diet (11, 12) . A preliminary analysis of 11␤-HSD1 expression in chow diet-fed LDLR Ϫ/Ϫ and A y /a;LDLR Ϫ/Ϫ mice indicated that a significant increase in enzyme expression in a representative fat pad was associated with obesity in aged A y /a; LDLR Ϫ/Ϫ mice (Fig. 1A) . We observed no such change for liver 11␤-HSD1 expression levels (Fig. 1B) .
To mice, UPLC-MS-MS of 11-DHC-to-corticosterone ratios revealed a statistically significant accumulation of 11-DHC substrate over corticosterone product in gonadal fat pads of CBXvs. vehicle-treated mice, further confirming an inhibitory effect of CBX on adipose tissue 11␤-HSD1 reductase activity (Fig. 1E) . CBX did not affect circulating systolic blood pressure. To exclude the possibility that CBX impacted blood pressure and, thus, possibly confounded an end point assessing the extent of atherosclerosis, systolic blood pressure was measured. Systemic administration of CBX had no effect on systolic blood pressure in LDLR Ϫ1 ⅐day Ϫ1 CBX also showed a similar, dose-dependent reduction in body weight. Body weight changes were reflected in differences in total fat mass (Fig. 2, B and E) . CBX treatment did not impact end-point muscle mass (Fig. 2, C and  F) . Consistent with the observed reductions in total fat mass, circulating leptin levels and gonadal fat pad weight were also dose dependently decreased with CBX treatment by the end of the study (Tables 1 and 2) .
CBX treatment results in negative energy balance. Confirming a hyperphagic effect of hypothalamic agouti protein overexpression in agouti mice (17) , cumulative food intake data revealed a significant difference between vehicle-treated LDLR Ϫ/Ϫ and A y /a;LDLR Ϫ/Ϫ controls: 59 Ϯ 4 and 75 Ϯ 2 g, respectively (P ϭ 0.01; Fig. 3A CBX compared with vehicle-treated controls that was attributable to a significant increase in light cycle energy expenditure (Fig. 3C) (9, 20, 28, 29, 34, 42) . In our study, neither male nor female LDLR Ϫ/Ϫ mice showed an effect of CBX treatment on circulating TG, TC, and FFA levels (Table 1) . However, CBXtreated male and female A y /a;LDLR Ϫ/Ϫ mice showed dosedependent and significant reductions in all measured lipids (P Ͻ 0.01 for TC and FFA, P Ͻ 0.05 for TG). Analysis of lipoprotein fractions revealed a selective reduction in the VLDL fraction (Fig. 4A) . Because changes in circulating VLDL levels can be a reflection of altered clearance or hepatic secretion, we determined whether these processes were impacted by CBX treatment. Using 125 I-VLDL tracer, we observed no effect on VLDL clearance due to CBX treatment in LDLR Ϫ/Ϫ mice (Fig.  4B) . In A y /a;LDLR Ϫ/Ϫ mice, CBX treatment resulted in a significant increase in VLDL clearance rate at an early time point, 10 min after injection of the VLDL tracer (P ϭ 0.0008). Hepatic TG production rate was not impacted by CBX in LDLR Ϫ/Ϫ mice but was significantly reduced in CBX-treated A y /a;LDLR Ϫ/Ϫ mice compared with vehicle-treated controls (P Ͻ 0.05; Fig. 4C neutral lipid content were attributable to significant differences in liver TG and unesterified cholesterol levels, as well as a trend toward decreased esterified cholesterol content; CBX treatment had no effect on hepatic phospholipid or FFA composition (Fig. 6B and data not shown) .
CBX treatment impacts hepatic gene expression. Hepatic TG and cholesterol content may be modulated by lipogenic processes, cholesterol synthesis, and cholesterol metabolism within the liver. Real-time PCR gene expression analysis revealed striking differences between LDLR Ϫ/Ϫ and A y /a; LDLR Ϫ/Ϫ vehicle-treated controls. Triacylglycerol hydrolase/ carboxylesterase, liver X receptor-␣, and cytochrome P-450 (CYP27A1) expression levels were increased 1.5-, 6.2-, and 2.2-fold in A y /a;LDLR Ϫ/Ϫ vehicle-treated relative to LDLR Ϫ/Ϫ vehicle-treated mice (P Ͻ 0.01, P ϭ 0.0002, and P Ͻ 0.0001, respectively). Consistent with the reductions in hepatic lipid content, key genes regulating hepatic TG and cholesterol accumulation were downregulated in CBX-treated LDLR
and A y /a;LDLR Ϫ/Ϫ mice (Table 3) .
DISCUSSION
We have shown that subcutaneous administration enables CBX to target liver and adipose tissue, both key metabolic tissues, ultimately resulting in profound metabolic changes in WD-fed LDLR Ϫ/Ϫ and A y /a;LDLR Ϫ/Ϫ hyperlipidemic mouse models of obesity. In A y /a;LDLR Ϫ/Ϫ mice, CBX treatment reduced plasma VLDL levels due to a small increase in the rate of VLDL uptake and a more dramatic decrease in the rate of hepatic TG production. The extent of atherogenesis, as assessed at the aortic root, was also significantly reduced in CBX-treated A y /a;LDLR Ϫ/Ϫ mice despite the short (4-wk) treatment period. In LDLR Ϫ/Ϫ and A y /a;LDLR Ϫ/Ϫ mice, CBX treatment ameliorated hepatic steatosis due to reductions in liver TG and unesterified cholesterol content. This was associated with decreased expression of genes involved in hepatic lipogenesis, cholesterol synthesis, and cholesterol metabolism. These results highlight a role of 11␤-HSD1 activity in the regulation of VLDL metabolism and secretion, as well as adiposity, insulin sensitivity, hepatic steatosis, and atherosclerosis, all of which are associated with metabolic syndrome in humans.
We chose to use the nonselective 11␤-HSD inhibitor CBX at the onset of our study, because it was the only commercial 11␤-HSD inhibitor available at the time. Since the initiation of our study, several specific 11␤-HSD1 inhibitors have been characterized and utilized in rodent studies (1, 8, 20) . However, CBX is commonly used in studies assessing the outcomes of modulation of 11␤-HSD1 enzyme activity in humans (4, 47, 51, 56, 58) . Although use of CBX as a long-term treatment for patients with the metabolic syndrome is limited because of its well-established hypertensive and hypokalemic side effects, resulting from inhibition of renal 11␤-HSD2 (45), the results of the present study suggest that specific inhibition of 11␤-HSD1 may be particularly beneficial in humans diagnosed with more than one metabolic syndrome risk factor. For the purpose of our study, the lack of effect of CBX on systolic blood pressure eliminated the need for concern regarding possible confounding effects of hypertension on atherogenesis. Moreover, we sought to address metabolic outcomes in liver and adipose tissue, both of which highly express 11␤-HSD1 and only minimally, if at all, express 11␤-HSD2. Similar to its naturally occurring analog glycyrrhetinic acid, CBX is also a potent gap junction blocker (13) , and this activity itself may impact adipogenesis (60) , hormonal regulation of hepatocyte function (16, 36, 37) , and macrophage response at sites of inflammation (15) . Therefore, results reporting CBX effects on metabolism may be subject to the confounding effects of CBX nonspecificity and, thus, must be interpreted with caution.
Route of administration may impact the ability of CBX to reach various adipose tissue depots. Previously published results in rats and humans utilizing orally administered CBX to inhibit 11␤-HSD1 indicated that this regimen impacts predominantly liver, with no detectable effect on adipose 11␤-HSD1 activity (28, 51) . More recently, however, effective targeting of 11␤-HSD1 activity in adipose tissue of healthy human subjects has been shown using orally administered CBX (56) . For our study, subcutaneous injection was chosen as a route of treatment, as subcutaneous injection was hypothesized to allow more of the CBX to bypass first-pass hepatic metabolism that may occur with oral ingestion, thus potentially enabling more of the drug to target adipose tissue. Indeed, tissue levels of CBX 1 h after injection were ϳ175-and 60-fold higher than published IC 50 values in liver and adipose tissue, respectively (7).
In striking contrast to studies utilizing orally administered CBX to inhibit liver 11␤-HSD1, subcutaneous CBX injection resulted in additional metabolic improvements, such as blunted weight gain and reduced fasting insulin, in our unique mouse models (28, 51) . The effect of CBX on weight gain was due to selectively and dose dependently decreased total body fat mass, with no detectable change in lean body mass, revealing that the drug treatment was not causing wasting in the mice. In CBX-treated A y /a;LDLR Ϫ/Ϫ mice, decreased body fat mass was attributable to negative energy balance due to increased basal metabolic rate. Transgenic modulation of adipose tissue glucocorticoid regeneration in mice has been shown to impact energy expenditure (23, 30) , and it is possible that inhibition of adipose tissue 11␤-HSD1 activity was key to the effects on energy expenditure, and thus obesity, in our mice. However, effects of CBX-mediated 11␤-HSD1 inhibition on other metabolic tissues involved in energy expenditure, such as skeletal muscle and brown adipose tissue, cannot be excluded. For instance, Berthiaume et al. (9) recently reported that, in a rat model of diet-induced obesity, 3 wk of treatment with a specific 11␤-HSD1 inhibitor resulted in elevated lipid oxidation product accumulation and/or increased expression of genes involved in fatty acid oxidation in brown adipose tissue, heart, and skeletal muscle.
Hermanowski-Vosatka et al. (20) utilized a specific 11␤-HSD1 inhibitor to determine effects on plasma lipids in lean, hyperlipidemic apolipoprotein E Ϫ/Ϫ mice. During the preparation of our manuscript, two more reports emerged regarding the effects of 11␤-HSD1-specific inhibition on white adipose tissue lipolysis and plasma TGs (9, 56). The results from the present study not only confirm that 11␤-HSD1 inhibition mice, a significant and dramatic reduction was observed in the expression of hepatic triacylglycerol hydrolase/ carboxylesterase 3, an enzyme involved in the mobilization of TG from hepatocyte lipid droplets during VLDL assembly (18) . Moreover, glucocorticoids are well established to increase VLDL secretion by the liver, and it is possible that the effect on hepatic TG production rate in A y /a;LDLR Ϫ/Ϫ mice was partially due to an inhibitory effect of CBX on local glucocorticoid regeneration.
Consistent with decreased hepatic TG and cholesterol content in LDLR Ϫ/Ϫ and A y /a;LDLR Ϫ/Ϫ mice, we observed reduced liver expression of several genes involved in de novo lipogenesis and cholesterol synthesis and metabolism. CBXmediated inhibition of adipose tissue glucocorticoid regeneration may have impacted hepatic steatosis. 11␤-HSD1 expression in adipose tissue is elevated in obese rats and humans (10, 22, 27, 46) . It has been proposed that a resulting increased flux of glucocorticoids regenerated by visceral adipose tissue enters the portal circulation, impacting glucocorticoid-mediated events at sites within the splanchnic bed (3, 30) . In this manner, adipose-derived glucocorticoids may modulate the expression of lipogenic genes in hepatocytes. Alternatively, CBX-mediated inhibition of local glucocorticoid regeneration within hepatocytes may also have impacted lipogenic gene expression. In keeping with an inhibitory effect of CBX on glucocorticoid regeneration, reductions in liver expression of CYP7A1, a glucocorticoid-inducible gene (44) , were observed in LDLR Ϫ/Ϫ and A y /a;LDLR Ϫ/Ϫ mice treated with CBX compared with vehicle-treated controls. However, possible confounding effects of CBX on 5␤-reductase activity (25) , and thus hepatic cholesterol metabolism, cannot be excluded from our interpretation of these data.
Only A y /a;LDLR Ϫ/Ϫ mice showed significant decreases in aortic root lesion area with CBX treatment, and this effect is most likely due to effects of the drug on plasma lipid levels. However, because VLDL induces lipid loading as well as proinflammatory cytokine expression in macrophages (52, 54) , reductions in circulating VLDL may have attenuated atherogenesis not only by impacting lipid accumulation, but also by decreasing inflammation at the site of the lesions. In addition, as speculated by Hermanowski-Vosatka et al. (20) , local inhibition of 11␤-HSD1 in the arterial wall may also impact atherogenesis. This hypothesis is supported by our data showing a trend in reduction of lesion area, despite the absence of effect on plasma lipids, in CBX-treated LDLR Ϫ/Ϫ mice. Alternatively, as increased adiposity is associated with elevated circulating proinflammatory cytokines and reduced secretion of the atheroprotective adipokine adiponectin, the effect of differences in adiposity due to CBX treatment on these factors, and thus atherogenesis, cannot be excluded.
Taken together, our results support the hypothesis that 11␤-HSD1 activity influences obesity, dyslipidemia, and atherosclerosis, which are risk factors or outcomes of the metabolic syndrome. Our findings hold key implications for future therapies aiming to inhibit 11␤-HSD1 in patients with metabolic syndrome, highlighting the importance of inhibitors created to selectively target adipose tissue enzyme activity.
